Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 Accounts Payable

As of the most recent data (June 2026), CYCCP shows a accounts payable of $190K. That compares with $220 in the prior-year period — up 85420.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYCCP's accounts payable is now $190K (was $220) — a 85420.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is outperforming or lagging.

Tracking CYCCP's accounts payable over time shows whether Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is scaling, shrinking, or reshaping that part of the business. The current reading is $190K That compares with $220 in the prior-year period — up 85420.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $190K) with ownership activity and broader fundamentals.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's accounts payable is $190K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.